Company Analysis

Beam Therapeutics Inc. (BEAM)

Nasdaq: BEAM · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2018
Grade6.4
◀ Past 6.9● Present 6.6▶ Future 5.5
1 est.

Who runs Beam Therapeutics Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Evans John M.
CEO. First filing Feb 2020, latest Oct 16, 2026, 24 filings in all.
Officers reporting now
6
of 12 people with a filing in the last fifteen months
Directors reporting now
6
17 people on the record since 2020
Officerssales are open-market, Oct 16, 2025 to Oct 16, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Evans John M.CEOFeb 2020Oct 16, 202613 · $6.2M
Cavanagh Bethany JSVP, Finance and TreasurerAug 2024Oct 2, 20264 · $400,000
Ciaramella GiuseppePresidentFeb 2020Sep 25, 20262 · $1.4M
Simon AmyChief Medical OfficerMar 2023Jul 29, 20263 · $600,000
Bellon ChristineChief Legal OfficerMar 2023Apr 6, 20266 · $900,000
Emany Sravan KumarChief Financial OfficerDec 2024Apr 2, 20261 · $200,000
Directorssales are open-market, Oct 16, 2025 to Oct 16, 2026
NameRoleFirst filingLatest filingSales, 12 months
Cooper Graham KdirectorFeb 2020Jun 5, 2026none
Fishman MarkdirectorFeb 2020Jun 5, 2026none
Guindo ChirfidirectorDec 2024Jun 5, 2026none
Maraganore JohndirectorNov 2021Jun 5, 2026none
Shaw ChristidirectorDec 2023Jun 5, 2026none
Walsh Kathleen EdirectorJan 2021Jun 5, 2026none
Owners of more than 10% of a classsales are open-market, Oct 16, 2025 to Oct 16, 2026
NameRoleFirst filingLatest filingSales, 12 months
Fmr LLC10% ownerFeb 2020Jun 29, 20263 · $10.1M
Earlier names on the record14, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton BEAM · research, not advice